A severe case of neuro-Sjögren's syndrome induced by pembrolizumab

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Ghosn, Jaqueline ^a   Vicino, Alex ^a   Michielin, Olivier ^a   Coukos, George ^a,b   Kuntzer, Thierry ^a   Obeid, Michel ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Checkpoint inhibitors; Immune related adverse events; Neuro Sj gren's syndrome; PD 1; Pembrolizumab

Indexed keywords

ACICLOVIR; ANTINUCLEAR ANTIBODY; BILIRUBIN; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATINE KINASE; CYCLOPHOSPHAMIDE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MEPREDNISONE; MYELOPEROXIDASE; PEMBROLIZUMAB; PREDNISONE; RITUXIMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CARPAL TUNNEL SYNDROME; CASE REPORT; CLINICAL ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MELANOMA; NERVE POTENTIAL; NEUROLOGIC DISEASE ASSESSMENT; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL NEUROPATHY LIMITATION SCALE; PLEOCYTOSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SJOEGREN SYNDROME; SKIN TINGLING; BIOPSY; BRAIN; DIAGNOSTIC IMAGING; PATHOLOGY; SALIVARY GLAND; TOXICITY AND INTOXICATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOPSY; BRAIN; FEMALE; HUMANS; MELANOMA; NEUROTOXICITY SYNDROMES; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 85055207067     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0429-4     Document Type: Article

References (19)

1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-68.
2. Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216-22.
3. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521-32.
4. Andtbacka R.H. et al., Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. https://doi.org/10.1200/JCO.2014.58.3377. Epub 2015 May 26.
5. Camdessanche JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, Antoine JC. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132(Pt 7):1723-33.
6. Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973-6.
7. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, et al. 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45.
8. Camdessanche JP, Jousserand G, Franques J, Pouget J, Delmont E, Creange A, Kuntzer T, Maisonobe T, Abba K, Antoine JC, et al. A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: a French collaborative study. J Peripher Nerv Syst. 2012;17(3):331-40.
9. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30(3):255-68.
10. Antoine JC, Robert-Varvat F, Maisonobe T, Creange A, Franques J, Mathis S, Delmont E, Kuntzer T, Lefaucheur JP, Pouget J, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci. 2016;361:187-91.
11. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, Katsuno M, Fujita A, Aiba I, Ogata A, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518-34.
12. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773-81.
13. Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26(2):202-4.
14. King J, de la Cruz J, Lutzky J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer. 2017;5:19.
15. Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:8.
16. Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, et al. Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis. 2018;77(3):468-70.
17. Harrington KJ, Michielin O, Malvehy J, Pezzani Gruter I, Grove L, Frauchiger AL, Dummer R. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 2017;10:3867-80.
18. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368-76.
19. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.